CRSP
CRISPR Therapeutics AGNASDAQHealthcare$49.51+1.43%ClosedMarket Cap: $4.75B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.32
P/S
1815.21
EV/EBITDA
-7.74
DCF Value
$-0.57
FCF Yield
-7.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-8560.0%
Operating Margin
-25384.7%
Net Margin
-22215.4%
ROE
-31.5%
ROA
-25.7%
ROIC
-31.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $864.0K | -6770.8% | $-154.8M | $-130.6M | $-1.37 | — |
| FY 2025 | $3.5M | -6537.0% | $-568.3M | $-581.6M | $-6.47 | — |
| Q3 2025 | $889.0K | -7177.1% | $-132.1M | $-106.4M | $-1.17 | — |
| Q2 2025 | $0.00 | -Infinity% | $-229.3M | $-208.5M | $-2.40 | — |
| Q1 2025 | $865.0K | -6548.4% | $-148.4M | $-136.0M | $-1.58 | — |
| Q4 2024 | $35.0M | 100.0% | $-64.6M | $-37.3M | $-0.44 | — |
| FY 2024 | $35.0M | -215.0% | $-466.6M | $-366.3M | $-4.34 | — |
| Q3 2024 | $0.00 | -Infinity% | $-110.1M | $-85.9M | $-1.01 | — |
| Q2 2024 | $517.0K | -10920.5% | $-151.3M | $-126.4M | $-1.49 | — |
| Q1 2024 | $504.0K | -10177.6% | $-140.6M | $-116.6M | $-1.43 | — |
| Q4 2023 | $200.0M | 90.0% | $69.6M | $89.3M | $1.10 | — |
| FY 2023 | $370.0M | 64.8% | $-222.5M | $-153.6M | $-1.94 | — |